Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment
Materials · 21.04.2026 · 19 (8) · 1664
DOI: 10.3390/ma19081664 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Materials, online erschienen am 21.04.2026. Verfasst von Valeria Flores und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioingeniería Traslacional, Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI), Universidad de Guadalajara, Guadalajara 4…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico.
Abstract (Originalsprache)
Cancer remains a primary global health challenge, accounting for millions of new cases and significant mortality annually. Although doxorubicin (DOX) is a fundamental anthracycline used for various malignancies, its therapeutic index is severely limited by poor selectivity, systemic toxicity, and dose-dependent cardiotoxicity. To address these issues, Janus nanoparticles (JNPs) have emerged as a promising bifunctional platform characterized by a structural asymmetry that allows for the independent functionalization of each hemisphere. This review examines primary fabrication routes—such as masking, microfluidics, self-assembly, and phase separation—and their specific applications in DOX delivery. The anisotropic architecture of JNPs enables a “separate rooms” concept, allowing for the co-delivery of incompatible drugs while facilitating multi-stimuli-responsive release mechanisms triggered by pH, enzymes, or NIR light. Furthermore, JNPs have demonstrated enhanced tumor accumulation and reduced systemic toxicity compared to conventional isotropic carriers. Recent developments even highlight the use of autonomous nanomotors to improve therapeutic delivery while minimizing premature leakage. However, clinical translation is currently hindered by manufacturing complexity, high equipment costs, scalability issues, and a lack of standardized reporting in the literature. Ultimately, JNPs represent a sophisticated frontier in precision oncology, though robust manufacturing processes and characterization protocols are required for future medical adoption.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Bioingeniería Traslacional, Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI), Universidad de Guadalajara, Guadalajara 44430, Mexico.
- Departamento de Física, Universidad Técnica Federico Santa María, Valparaíso 2390123, Chile.
- Departamento de Ciencias Físicas y Matemáticas, Universidad Católica de Temuco, Temuco 4813302, Chile.
- Núcleo de Investigación en Bioproductos y Materiales Avanzados (BioMA), Universidad Católica de Temuco, Temuco 4813302, Chile.
ORCID-Profile: Valeria Flores, Moniellen Pires Monteiro, Jacobo Hernandez-Montelongo
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
Zitieren
APA
Flores, V., Monteiro, M. P., Plaza, T., & Hernandez-Montelongo, J. (2026). Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment. Materials, 19(8), 1664. https://doi.org/10.3390/ma19081664
Vancouver
Flores V, Monteiro MP, Plaza T, Hernandez-Montelongo J. Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment. Materials. 2026;19(8):1664. doi:10.3390/ma19081664
BibTeX
@article{Flores2026,
author = {Flores, Valeria and Monteiro, Moniellen Pires and Plaza, Tanya and Hernandez-Montelongo, Jacobo},
title = {Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment},
journal = {Materials},
year = {2026},
volume = {19},
number = {8},
pages = {1664},
doi = {10.3390/ma19081664}
}
EUVIMED